Pfizer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Comment on "Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines"
J Immunol. 2024 Mar 1;212(5):753. doi: 10.4049/jimmunol.2300425.NO ABSTRACTPMID:38377475 | DOI:10.4049/jimmunol.2300425 (Source: Journal of Immunology)
Source: Journal of Immunology - February 20, 2024 Category: Allergy & Immunology Authors: Abraham Al-Ahmad Source Type: research

Clinical characteristics and risk factors of non-mild outcomes in patients with Omicron variant COVID-19 in Shanghai, China
CONCLUSIONS: Our results call for special concern for full and booster vaccination of the elderly, which will effectively protect from progression of COVID-19 to non-mild state. In the meantime, symptomatic COVID-19 patients should be treated as soon as possible.PMID:38377093 | DOI:10.3855/jidc.18138 (Source: Cancer Control)
Source: Cancer Control - February 20, 2024 Category: Cancer & Oncology Authors: Wen Zhu Haowei Wang Hai Zhou Lei Cheng Chao Weng Source Type: research

Viral Reactivation Following COVID-19 Vaccination: a review of the current literature
Clin Exp Dermatol. 2024 Feb 20:llae061. doi: 10.1093/ced/llae061. Online ahead of print.ABSTRACTBACKGROUND: Currently, four vaccines for COVID-19 have been licensed by the European Medi-cines Agency: viral vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2. and 2 mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273). Since their approval, several cutaneous reactions related to vaccination have been reported in the literature. Among these, viral reactivations are one of the most frequent.OBJECTIVES: The aim of this manuscript was to investigate current literature regarding vira...
Source: Herpes - February 20, 2024 Category: Infectious Diseases Authors: Fabrizio Martora Matteo Megna Teresa Battista Massimiliano Scalvenzi Alessia Villani Sara Cacciapuoti Luca Potestio Source Type: research

Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies
The coronavirus disease 2019 (COVID-19) pandemic triggered an unprecedented concentration of economic and research efforts to generate knowledge at unequalled speed on deregulated interferon type I signalling and nuclear factor kappa light chain enhancer in B-cells (NF-κB)-driven interleukin (IL)-1β, IL-6, IL-18 secretion causing cytokine storms. The translation of the knowledge on how the resulting systemic inflammation can lead to life-threatening complications into novel treatments and vaccine technologies is underway. Nevertheless, previously existing knowledge on the role of cytoplasmatic or circulating self-DNA as ...
Source: Frontiers in Immunology - February 19, 2024 Category: Allergy & Immunology Source Type: research

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study
We examined associations between long (≤89 days) versus short (<89 days) between-dose intervals and antibody response through multivariable mixed-effects models adjusted for age, sex, prior covid infection status, time since vaccine dose, and assay batch.FindingsThe cohort included 328 participants who received up to three vaccine doses (>80% Pfizer-BioNTech). Weighted averages of the serum (n=744) and DBS (n=216) cohort results from the multivariable models showed that IgG anti-S was 31% higher (95% CI: 12% to 53%) and IgG anti-RBD was 37% higher (95% CI: 14% to 65%) in the long vs. short interval participants, ac...
Source: Frontiers in Immunology - February 16, 2024 Category: Allergy & Immunology Source Type: research

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies
This study aimed to delineate longitudinal antibody responses to the Pfizer-BioNTech BNT162b2 COVID-19 vaccine within the Ugandan subset of the Sub-Saharan African (SSA) demographic, filling a significant gap in global datasets.MethodsWe enrolled 48 participants and collected 320 specimens over 12 months after the primary vaccination dose. A validated enzyme-linked immunosorbent assay (ELISA) was used to quantify SARS-CoV-2-specific IgG, IgM, and IgA antibody concentrations (ng/ml) and optical densities (ODs). Statistical analyses included box plots, diverging bar graphs, and the Wilcoxon test with Bonferroni correction.Re...
Source: Frontiers in Immunology - February 16, 2024 Category: Allergy & Immunology Source Type: research

Viruses, Vol. 16, Pages 292: Performance of Three Anti-SARS-CoV-2 Anti-S and One Anti-N Immunoassays for the Monitoring of Immune Status and Vaccine Response
This study aimed to evaluate and compare the performance of three anti-S and one anti-N assays that were available to the project in detecting antibody levels after three commonly used SARS-CoV-2 vaccines (Pfizer, Moderna, and Johnson &amp; Johnson). It also aimed to assess the association of age, sex, race, ethnicity, vaccine timing, and vaccine side effects on antibody levels in a cohort of 827 individuals. In September 2021, 698 vaccinated individuals donated blood samples as part of the Association for Diagnostics &amp; Laboratory Medicine (ADLM) COVID-19 Immunity Study. These individuals also participa...
Source: Viruses - February 14, 2024 Category: Virology Authors: Y. Victoria Zhang Attila Kumanovics Joesph Wiencek Stacy E. F. Melanson Tanzy Love Alan H. B. Wu Zhen Zhao Qing H. Meng David D. Koch Fred S. Apple Caitlin R. Ondracek Robert H. Christenson Tags: Article Source Type: research

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
In conclusion, COVID-19 vaccination was not found to be associated with an increased risk of HZ-related admission and complications.PMID:38348725 | DOI:10.2340/actadv.v104.18389 (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - February 13, 2024 Category: Dermatology Authors: Shir Azrielant Yair Levin Alon Peled Liat Samuelov Eli Sprecher Mor Pavlovsky Source Type: research

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
In conclusion, COVID-19 vaccination was not found to be associated with an increased risk of HZ-related admission and complications.PMID:38348725 | DOI:10.2340/actadv.v104.18389 (Source: Herpes)
Source: Herpes - February 13, 2024 Category: Infectious Diseases Authors: Shir Azrielant Yair Levin Alon Peled Liat Samuelov Eli Sprecher Mor Pavlovsky Source Type: research

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
In conclusion, COVID-19 vaccination was not found to be associated with an increased risk of HZ-related admission and complications.PMID:38348725 | DOI:10.2340/actadv.v104.18389 (Source: Acta Dermato-Venereologica)
Source: Acta Dermato-Venereologica - February 13, 2024 Category: Dermatology Authors: Shir Azrielant Yair Levin Alon Peled Liat Samuelov Eli Sprecher Mor Pavlovsky Source Type: research